Reproductive technology company Memphasys came out of a trading halt on Monday morning, telling investors that it has received binding commitments to raise $1.275 million through a strategic placement. In a statement to the ASX, Memphasys said the commitments were from new and existing shareholders, amounting to 212,500,000 ordinary shares at $0.006 per share. Participants…
Memphasys claims defining milestone for Felix Reproductive technology company Memphasys has announced the successful data from a “pivotal clinical trial” for the Felix System, “confirming its best-in-class performance in sperm selection for Assisted Reproductive Technology (ART).” Conducted in partnership through Monash IVF, Memphasys said on Monday that the trial results show Felix as “non-inferior to…
Tariff exemption consideration a welcome first step: Ai Group The agreement by US president Donald Trump to consider an exemption for Australian steel, aluminium and iron from a 25 per cent tariff is “a welcome first step to protect vital industries with more than 100,000 mostly regional jobs,” Innes Willox, Chief Executive of the Australian…
Clinical trials of its Felix sperm separation device for IVF clinics are now 90 per cent complete, according to reproductive technology specialist Memphasys, with the company also sharing that it now anticipates “entering larger markets earlier than previously expected” following a decision to pursue CE mark registration. In a statement on Thursday, the company told…
Orthocell’s strong sales growth Tissue regeneration technology developer Orthocell has announced sales growth across its product portfolio, with total revenue for FY24 of $6.72 million – up 30.40 percent from FY23. Record revenue of $1.84m was achieved for the June 24 Quarter, up 14.41 percent. With Striate+ currently sold in the US, Europe/UK, Australia and…
ASX-listed reproductive biotechnology company Memphasys has announced results showing “clear benefits” of its Felix technology versus two widely used technologies in a Japanese trial, with results from a larger-scale trial expected to be shared in late-2024. According to an ASX statement from the company on Monday, the Felix System (pictured) outperformed a sperm preparation method…
